The journal continues to celebrate its 50th anniversary year by examining important developments in the mental health field over the past five decades. Clozapine, the prototype atypical antipsychotic, was approved for use in 1990, and the reprinted 1993 article by Alan Brier, M.D., and his colleagues reports 12-month outcomes for a group of chronically ill outpatients taking clozapine (see page 1249). The study results supported those found in clinical trials. More than half of the patients responded to the new medication. They experienced sustained improvement in positive symptoms and significantly fewer hospitalizations. In a related commentary, Jeffrey A. Lieberman, M.D., and his colleagues discuss the significant changes brought about by the introduction of second-generation medications, including atypical antipsychotics and selective serotonin reuptake inhibitors (page 1254). In Taking Issue, Robert A. Rosenheck, M.D., notes that although it is important to celebrate the undeniable progress in pharmacotherapy, we should be cautious in not misleading the public (page 1213).